8-K: TransCode Acquires Polynoma, Secures $25M Financing

TransCode Therapeutics expands its oncology pipeline with the acquisition of Polynoma and secures a $25 million strategic investment from CK Life Sciences, appointing a new CEO and Board member.

Summary

• TransCode Therapeutics acquired 100% of Polynoma LLC, an immuno-oncology company, from DEFJ, LLC (a subsidiary of CK Life Sciences Intl., (Holdings) Inc.) on October 8, 2025.
• The acquisition consideration included 83,285 shares of TransCode common stock (9.99% of shares outstanding immediately prior to closing) and 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock.
• Concurrently, TransCode received a $25 million strategic investment from DEFJ, LLC, consisting of approximately $20 million in cash and a $5 million promissory note, in exchange for 223.7337 shares of Series B Non-Voting Convertible Preferred Stock.
• DEFJ (CK Life Sciences) will hold approximately 91% of TransCode on a fully diluted basis post-transaction, with pre-acquisition stockholders holding approximately 9%, valuing the combined entity at approximately $165 million fully diluted equity.
• TransCode's pipeline now includes Polynoma's Phase 3-ready seviprotimut-L, a melanoma vaccine, alongside its lead microRNA asset, TTX-MC138, which is funded to advance into a Phase 2 clinical trial.
• Philippe Calais, PharmD, PhD, was appointed Chief Executive Officer, while Thomas Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, joined the Board as an independent director and Audit Committee Chairperson.
• Existing TransCode stockholders of record as of October 20, 2025, will receive a non-transferable Contingent Value Right (CVR) entitling them to 50% of net proceeds from future corporate partnering of TTX-MC138.
• DEFJ has a repurchase option for ABCJ's interests under certain Triggering Events, including regulatory or listing failures, or delays in clinical trials or registration statements.

Sentiment

Score: 8

Explanation: The acquisition of a Phase 3-ready asset and securing $25 million in financing significantly de-risks the company's pipeline and provides capital for its lead program. While there is substantial dilution for existing shareholders and the CVRs are speculative, the overall strategic positioning and funding for clinical advancement are strong positives. New leadership and board appointments also contribute to a positive outlook.

Positives

• Significant expansion of the oncology pipeline with the addition of Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for melanoma.
• Secured $25 million in strategic financing, including approximately $20 million in cash, which is primarily allocated to advance the lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
• New leadership with Philippe Calais appointed as CEO, bringing extensive biotech and pharmaceutical industry experience, and Elizabeth Czerepak joining the Board as an independent director and Audit Committee Chairperson.
• Potential for up to $95 million in contingent milestone payments related to seviprotimut-L, indicating future value generation.
• The CVR distribution to existing stockholders provides a mechanism for them to potentially benefit from future monetization of TTX-MC138, aligning interests.
• The acquisition creates a unique immuno-oncology and metastatic prevention oncology company, potentially realizing synergies between the TTX-MC138 and seviprotimut-L technologies.

Negatives

• Significant dilution for pre-acquisition stockholders, who will own approximately 9% of the combined entity on a fully diluted basis, compared to CK Life Sciences' approximately 91%.
• The $5 million portion of the $25 million investment is a promissory note, not immediate cash, and is secured by Series B Preferred Stock, indicating a debt component.
• The CVRs are non-transferable and "highly speculative," with no assurance of any payments, potentially limiting their immediate value to stockholders.
• The Repurchase Agreement grants DEFJ an option to re-acquire ABCJ's interests upon various Triggering Events, including regulatory or listing failures, which could unwind the acquisition under certain adverse circumstances.
• The company will incur expenses related to seeking stockholder approval for the Preferred Stock conversion and change of control, and for maintaining Nasdaq listing.

Risks

• Stockholder Approval Risk: Conversion of Preferred Stock and change of control require stockholder approval, which is not guaranteed and could delay or prevent full integration and financing benefits.
• Regulatory and Listing Compliance Risk: Failure to obtain Nasdaq listing approval for new shares or maintain existing listing could trigger DEFJ's repurchase option.
• Clinical Development Risk: Delays in dosing the first patient in seviprotimut-L's clinical trial by the third anniversary of stockholder vote could trigger DEFJ's repurchase option.
• Registration Statement Effectiveness Risk: Failure to have the resale registration statement for DEFJ's shares declared effective by June 30, 2026, or a 90-day Registration Default, could trigger DEFJ's repurchase option.
• CVR Payment Uncertainty: CVR payments are "highly speculative" and "subject to numerous factors outside of the Company’s control," with no assurance that holders will receive any payments.
• Integration Risk: Integrating Polynoma's operations and pipeline may present challenges, potentially impacting efficiency and expected synergies.
• Financial Performance Risk: The company requires substantial additional capital, as noted in forward-looking statements, indicating ongoing funding needs beyond this transaction.
• Promissory Note Risk: The $5 million promissory note is due January 1, 2026, and accrues interest, requiring repayment in the near term.

Future Outlook

The company plans to advance its lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial, funded by the strategic investment. It will also pursue the development of Polynoma's Phase 3-ready seviprotimut-L and explore synergies between the two technologies. Stockholder approval is required for the conversion of preferred stock and a change of control under Nasdaq rules, with a proxy statement to be filed within 30 days of receiving financial statements. The company will hold stockholder meetings at least every six months until these approvals are obtained.

Management Comments

• "I am very honored to deepen my commitment and lead TransCode’s transformation into a one-of-a-kind leading oncology company at this critical time."
• "We are grateful for CK Life Sciences’ investment and their support of our miRNA candidate, TTX-MC138, as we now have the funding in place to fully execute our upcoming TTX-MC138 Phase 2."
• "This acquisition allows us to create a unique and broader pipeline with Phase 3 ready seviprotimut-L, and potentially realize synergies between both technologies, for the ultimate benefit of patients suffering from cancer and metastases."
• "Between the two programs, we see a unique potential to augment seviprotimut-L’s focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients."
• "Finally, I express my gratitude to Tom Fitzgerald for his remarkable dedication and commitment as he steps down from the Interim Chief Executive Officer position to revert to his previous role as Chief Financial Officer."
• "I extend a warm welcome to all our new colleagues transitioning from Polynoma and to Elizabeth Czerepak, our new Independent Board member."
• "All the ingredients are now in place to fully execute on our ambitious plan and deliver value to our shareholders."

Industry Context

This announcement positions TransCode Therapeutics as a more diversified oncology company, combining its RNA-targeted therapeutics platform (TTX-MC138 for metastatic cancer) with a late-stage immuno-oncology asset (seviprotimut-L vaccine for melanoma). The move aligns with broader industry trends towards combination therapies and leveraging different modalities (RNA, vaccines) to address complex cancers, particularly metastatic disease which accounts for over 90% of cancer deaths. The strategic investment from CK Life Sciences, a listed entity on the Hong Kong Stock Exchange, also highlights increasing global interest and investment in innovative oncology treatments.

Comparison to Industry Standards

• Seviprotimut-L is positioned against checkpoint inhibitors like Keytruda (Merck) and Opdivo (BMS) for adjuvant melanoma treatment, claiming advantages of significantly safer profile (no severe, long-term, or chronic side effects), lower cost (product and treatment), broader applicability (can be used in all patients, unlike CPIs with <50% response rates and unreliable selection methods), and potential for use first-line or in combination without affecting CPI efficacy.
• TTX-MC138, targeting microRNA-10b, represents a novel genetic target approach in RNA therapeutics, distinct from traditional oncology treatments. Phase 0 results demonstrating successful delivery to metastatic lesions and robust pharmacodynamic activity at a microdose are positive indicators for its competitive positioning.
• The acquisition of a Phase 3-ready asset significantly strengthens TransCode's pipeline, providing a more advanced clinical candidate compared to many early-stage biotech companies that rely solely on preclinical or early-phase programs.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of Polynoma LLC from DEFJ, LLC, which is a subsidiary of CK Life Sciences Intl., (Holdings) Inc.
• The $25 million strategic investment from DEFJ, LLC.
• The issuance of 83,285 shares of common stock and 1,152.9568 shares of Series A Preferred Stock to DEFJ, LLC.
• The issuance of 223.7337 shares of Series B Preferred Stock to DEFJ, LLC.
• The Repurchase Agreement granting DEFJ, LLC an option to re-acquire ABCJ's interests.
• The Registration Rights Agreement granting DEFJ, LLC certain registration rights.
• The appointment of a Seller Nominee to the Board of Directors, with increased representation after stockholder approval.

Stakeholder Impact

• Shareholders (Pre-acquisition): Experience significant dilution (from ~100% to ~9% fully diluted ownership). However, they receive CVRs for potential future upside from TTX-MC138 and benefit from the company's strengthened pipeline and financing.
• New Investor (CK Life Sciences/DEFJ): Becomes the majority shareholder (~91% fully diluted), gains control of the company, and has significant board representation. Provides strategic capital and a Phase 3 asset.
• Employees: TransCode expects to retain several finance, development, and manufacturing professionals from Polynoma, indicating potential integration and new opportunities. Management roles have been clarified and compensated.
• Customers/Patients: The expanded pipeline, particularly with a Phase 3-ready asset and funded Phase 2 for TTX-MC138, offers potential for new and advanced oncology treatments.
• Creditors: The $5 million promissory note represents a new debt obligation for TransCode, due January 1, 2026.

Next Steps

• Prepare and file a proxy statement on Schedule 14A with the SEC within 30 days following receipt of all required financial statements from the Seller.
• Call and hold a stockholders meeting to seek approval for the conversion of Series A and Series B Preferred Stock into Common Stock and a change of control under Nasdaq listing rules.
• Use commercially reasonable efforts to cause the initial registration statement for resale of Registrable Securities to be declared effective by the SEC as soon as practicable.
• Advance TTX-MC138 into a Phase 2 clinical trial.
• Continue development and commercialization efforts for seviprotimut-L.
• Authorize, nominate, and appoint the sixth director to the Purchaser Board as promptly as practicable, and in any event prior to December 31, 2025.
• File a final prospectus with the SEC by 9:30 A.M. New York City time on the first Business Day after the Effective Date of a registration statement.
• Maintain Nasdaq listing and submit a notification form for the listing of new shares.

Key Dates

Recommendation

This is a transformative transaction for TransCode, significantly expanding its pipeline with a late-stage asset and securing crucial funding. The new leadership and strategic investor backing are positive. However, the substantial dilution for existing shareholders (91% to new investor) and the speculative nature of the CVRs introduce considerable uncertainty. While the long-term potential is enhanced, the immediate impact on existing share value due to dilution and the need for stockholder approval for key aspects of the transaction warrant a cautious "hold" until more clarity emerges on integration, clinical progress, and the market's absorption of the dilution. The repurchase option also adds a layer of complexity and potential risk.

Keywords

TransCode Therapeutics, Polynoma, CK Life Sciences, Acquisition, Strategic Financing, Immuno-oncology, Metastatic Cancer, RNA Therapeutics, TTX-MC138, Seviprotimut-L, Cancer Vaccine, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Contingent Value Rights, Nasdaq Listing, Corporate Governance, Management Changes, Biopharmaceutical